Insider buying last 90 days
No open-market insider purchases were filed for HIMS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Hims & Hers Health slid this week after third-quarter 2026 results missed Wall Street's expectations on both revenue and earnings, compared with earnings of $0.06 per share a year ago. The company also narrowed its full-year revenue outlook as margins contracted, citing lower-than-expected third-quarter sales. Separately, Andrew Huberman was appointed to the company's Board of Directors, a move framed around his standing as a health and wellness commentator.
The stock closes at $22.94, down 11.8% on the day, with its close sitting between the 50-day average of $28.31 and the 200-day average of $26.87, pointing to a mixed trend. Returns over one, three and six months stand at -25.8%, -24.8% and -21.3% respectively, with a one-year return of -44.7%. The GekkoIndex reads 68.8, placing HIMS in the Accumulation zone, up 5.1 over five days. Price sits 51.3% below the Gekko Fair Value of $47.14.
No confirmed earnings date appears on the calendar following the 10 August 2026 report, so the next 20 trading days carry no scheduled print. Options activity shows 5 unusual signals over the past 30 days, with call premium of $8,330,191 against put premium of $2,819,157. Analyst consensus across 14 firms stands at 3 buy and 11 hold ratings, with a consensus target of $31.15. Seasonally, the next 20 trading days from this point have averaged +15.4% across 5 years, rising in 3 of them, a pattern worth noting given the stock's typical 20-day move of 15.9%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Hims & Hers Health scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Averages disagree
Close $19.73 sits between the 50-day ($27.61) and 200-day ($26.68) averages, or the averages disagree.
See the chart71.8, Buying
Reading 71.8 is in the Buying zone.
See the GekkoIndex49.7% below
Price is 49.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 7 unusual options signals.
See smart moneyReports in 99 days
Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.
See earnings+2.8% on average
From this point in the calendar, the next 20 trading days averaged +2.8% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Hims & Hers Health closed at $19.73 on Nov 13, 2026, −49.4% over the past year, inside a 52-week range of $13.74 to $40.99.
Use the left and right arrow keys to read daily values.
Put HIMS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Hims & Hers Health runs an online service that pairs customers with licensed clinicians for remote visits and follow-up care, reachable through its websites and a mobile app. It is recognized for bringing both prescription and everyday health items straight to consumers, with particular attention paid to wellness, sexual health, skincare, and hair care needs.
Customers can order ongoing prescription treatments as well as a range of over-the-counter goods, among them vitamin C, melatonin, biotin, and collagen protein supplements for general wellness, moisturizers, serums, and face washes for skin care, condoms, delay sprays, vibrators, and lubricants for sexual health, and shampoos, conditioners, scalp scrubs, and minoxidil treatments for hair care. The company also places some of its products with other sellers through wholesale deals, in addition to its direct-to-consumer sales.
Hims & Hers Health is based in San Francisco, California. Its stock trades on the NYSE under the ticker HIMS.
Hims & Hers Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.8, in the Buying zone, up 8.6 points over five sessions.
Up 8.6 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 46 | −2.5% | +10.3% |
| Accumulation | 220 | +1.6% | +13.3% |
| Neutral | 371 | +1.9% | +5.1% |
| Distribution | 54 | +4.9% | +4.7% |
| Selling | 11 | −0.1% | −3.2% |
Average HIMS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
Hims & Hers Health trades 49.7% below Gekko Fair Value of $39.21, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Hims & Hers Health shares are worth, recalculated every trading day.
$39.21
Gekko Fair Value, Nov 14, 2026
49.7% Undervalued
At the end of Aug 2026 the price was 6.1% below the estimate.
No open-market insider purchases were filed for Hims & Hers Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HIMS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HIMS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Hims & Hers Health has been buying back its own shares.
From company filings.
7signals, 75% of the flagged premium in calls.
Latest: Bullish flow on Nov 13, $277K in unusual premium.
3of the funds Gekko tracks hold HIMS.
Hims & Hers Health reports on Feb 22, 2027, after the close (99 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 22, 2027
Expected after the close, 99 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 9, 2026 | −$0.14 est $0.06 | $890.4M est $893.1M | −26.4% |
| Aug 10, 2026 | −$0.10 est −$0.07 | $753.2M est $698.9M | −3.4% |
| May 11, 2026 | −$0.40 est $0.13 | $608.1M est $616.8M | −11.5% |
| Feb 23, 2026 | $0.07 est $0.02 | $617.8M est $619.2M | −1.1% |
| Nov 3, 2025 | $0.06 est $0.09 | $599.0M est $618.1M | −5.9% |
| Aug 4, 2025 | $0.17 est $0.18 | $544.8M est $584.1M | −11.2% |
| May 5, 2025 | $0.20 est $0.12 | $586.0M est $538.6M | +21.2% |
| Feb 24, 2025 | $0.11 est $0.22 | $481.1M est $494.6M | −19.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Hims & Hers Health is $28.31, +43.5% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | KeyBanc | — | — |
| Nov 10 | Needham | $32 | +62.2% |
| Nov 10 | Morgan Stanley | $25 | +26.7% |
| Nov 10 | Leerink Partners | $24 | +21.6% |
| Nov 10 | J.P. Morgan | $24 | +21.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Hims & Hers Health averaged +2.8% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −7.8% | 1 of 5 |
| Next 10 trading days | +1.4% | 3 of 5 |
| Next 15 trading days | +5.8% | 4 of 5 |
| Next 20 trading days | +2.8% | 3 of 5 |
| Next 30 trading days | −3.0% | 2 of 5 |
For scale, HIMS’s typical 20-trading-day move in either direction is about 16.1%.
Hims & Hers Health’s market cap is $4.44B and revenue of $2.87B over the last twelve months.
Coverage of Hims & Hers Health this week reads negative: 1 positive, 0 neutral and 2 negative headlines.
Hims & Hers Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
A peer links to its own page where one exists.
Hims & Hers Health’s market cap is $4.44B at the Nov 13, 2026 close of $19.73, with 226.0M shares outstanding.
The consensus analyst 12-month price target for Hims & Hers Health is $28.31, +43.5% from the last close. Of the 12 firms that rated the stock in the last 90 days, 3 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Hims & Hers Health is undervalued: the Nov 13, 2026 close of $19.73 is 49.7% below Gekko Fair Value of $39.21. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Hims & Hers Health is expected to report on Feb 22, 2027, after the market closes (99 days away). Analysts expect earnings of $0.02 per share on revenue of $903.1M. Hims & Hers Health beat the earnings estimate in 2 of its last 8 reports, moving 12.5% on average across the report.
Hims & Hers Health’s 52-week high is $40.99 and its 52-week low is $13.74; it closed at $19.73 on Nov 13, 2026, −49.4% over the past year. Over the last five years the shares peaked at $72.98 on Feb 19, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
Gekko flagged 7 unusual options signals in Hims & Hers Health over the last 30 days, with $8.84M of flagged premium in calls and $2.95M in puts. The latest, bullish flow, was on Nov 13, 2026 with $277K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.